GSTM1 and chronic kidney disease: The data strongly suggest a target Hb in the CKD population no higher than 10–12 g/dL, careful attention to underlying risks for cardiovascular disease, and thorough evaluation of correctable causes of anemia to prevent “overuse” of ESAs.